Sign in
Taking peoplePhase 2

Shorter radiation course after surgery for thymic epithelial tumors

Tests the safety of shorter radiation after surgery in thymic epithelial tumors.

Key facts

Who runs it
Tianjin Medical University Cancer Institute and Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors
Status
Recruiting
Phase
Phase 2
People taking part
49 people, planned
Started
14 Jul 2026
Expected to end
30 Jun 2029
Type of study
Interventional
Treatments tested
  • Postoperative hypo-fractionated radiotherapy
Record updated
10 July 2026

Who can take part

The trial is looking for adults whose thymoma or thymic carcinoma (tumors of the thymus gland in the chest) was fully removed by surgery. They will get a shorter course of radiotherapy after surgery: 40 Gy in 15 sessions over 3 weeks.

Age
18 to 75 years
Sex
Male or female
Disease stage
Masaoka-Koga stage II-III thymic carcinoma, stage IIA type B3 thymoma, stage IIB type B2/B3 thymoma, or stage III thymoma. People must be fully active or only mildly limited (ECOG 0-1), with a life expectancy of at least 3 months.
Earlier treatment
People must have had complete (R0) surgical removal of the tumor. People who had radiotherapy to the chest before cannot join. People who had other cancer treatment, such as immunotherapy, targeted therapy or experimental drugs, cannot join.
Main reasons for not taking part
  • No surgery, or surgery that left tumor behind (R1 or R2 resection, or visible tumor left)
  • Weak immune system, including HIV, an organ transplant, or a bone marrow transplant from a donor
  • Lung scarring disease (interstitial lung disease), past non-infectious lung inflammation, or poor lung function (grade 3 or higher)
  • Serious heart disease, such as heart failure NYHA class II or higher, unstable angina, or heart attack within 1 year
  • Active tuberculosis, hepatitis B or hepatitis C, or another cancer, except low-risk cancers that were treated
Show the full registry criteria (21)Hide the full registry criteria

Who can take part

  • Patients who voluntarily agree to participate in this study, sign the informed consent form, demonstrate good compliance, and are willing to comply with scheduled follow-up visits
  • Age 18-75 years, male or female
  • Histopathologically confirmed thymoma or thymic carcinoma after R0 complete resection. Eligible disease stages according to the Masaoka-Koga staging system include Stage II-III thymic carcinoma, Stage IIA Type B3 thymoma, Stage IIB Type B2/B3 thymoma, and Stage III thymoma
  • Eastern Cooperative Oncology Group performance status of 0-1
  • Life expectancy of at least 3 months
  • Adequate major organ function to meet the requirements of study treatment, including bone marrow, hepatic, renal, and coagulation function according to protocol-specified criteria
  • Patients with reproductive potential must agree to use medically acceptable contraception during study treatment and for 6 months after completion of study treatment. Female patients of childbearing potential must have a negative pregnancy test before enrollment and must not be breastfeeding

Who cannot take part

  • Prior thoracic radiotherapy
  • Major surgery other than the tumor resection procedure or severe trauma within 4 weeks before the first radiotherapy treatment
  • Prior or ongoing non-protocol-specified antitumor therapy, including immunotherapy, targeted therapy, radiotherapy, or other investigational treatment
  • Severe infection within 4 weeks before the first radiotherapy treatment, or active pulmonary inflammation indicated by baseline imaging
  • Patients who do not meet the protocol-specified requirements for pathological type, disease stage, or histological subtype
  • Patients who have not undergone surgical treatment, or who underwent R1 or R2 resection, or who have definite gross residual disease
  • Active autoimmune disease or a history of severe autoimmune disease that, in the investigator's judgment, makes the patient unsuitable for radiotherapy
  • History of immunodeficiency, including HIV positivity, history of organ transplantation, or history of allogeneic bone marrow transplantation
  • Uncontrolled severe cardiovascular disease, such as New York Heart Association Class II or higher heart failure, unstable angina, myocardial infarction within 1 year, or severe arrhythmia requiring clinical intervention
  • History of interstitial lung disease, history of non-infectious pneumonitis, or Grade 3 or higher pulmonary dysfunction confirmed by pulmonary function testing
  • Active pulmonary tuberculosis, active hepatitis B infection, or active hepatitis C infection
  • Diagnosis of another malignancy before the first radiotherapy treatment, except for low-risk malignancies that have been adequately treated
  • Any other condition that, in the investigator's judgment, may affect patient safety, compliance, or the collection of study data
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Thymic epithelial tumor

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a prospective, open-label, single-arm Phase II study designed to evaluate the safety of postoperative hypofractionated radiotherapy in patients with Stage II/III thymic epithelial tumors after complete resection. After a screening period of up to 28 days, eligible patients will receive adjuvant hypofractionated radiotherapy to a total dose of 40 Gy in 15 fractions, delivered once daily at 2.67 Gy per fraction, 5 days per week over 3 weeks. The study will primarily assess treatment-related safety and tolerability, with preliminary evaluation of efficacy, economic burden, and quality of life.

The group in the trial

  • RTTreatment being tested

    Treatment: Postoperative hypo-fractionated radiotherapy

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Single-Arm Phase II Clinical Study of Hypofractionated Adjuvant Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors
Plain-language title
Shorter radiation course after surgery for thymic epithelial tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07691619, who can take part
Record updated
10 July 2026